This week we look at NurOwn® for multiple sclerosis, a combination therapy failing to meet primary endpoint for glioblastoma and warnings from the US FDA.
Antidepressants are an effective treatment route for depression, novel study claims.
The hypothesis that antidepressant response has a relevant genetic component was initially suggested by the observation that this phenotype clusters in families.
Both lithium and rapamycin could prevent the secondary nerve cell damage caused by the overproduction of glutamate after a traumatic brain injury.
Veronika Kiryanova discusses her recent work on maternal stress and offspring mental health, and her thoughts on how research such as this could impact future research and clinical practice.
Comparative risk of hip fractures in elderly nursing home patients with depression using paroxetine and other selective serotonin reuptake inhibitors
In this research article, the authors evaluate the comparative safety of paroxetine and other SSRIs for the risk of hip fractures, finding no differential risk.
Meta-analysis shines a spotlight on the potential use of anti-inflammatories for the treatment of depression.
The authors assess the value of utilizing pharmacogenetic information to improve antidepressant drug therapy in BPD patients.
Identifying genetic loci affecting antidepressant drug response in depression using drug–gene interaction models
In this review, the researchers discuss the methodological challenges and limitations of the studies that have been conducted on this topic to date (e.g., ‘treated-only design’, statistical power) and discuss how specifically drug–gene interaction models can be used to be better able to identify genetic variants associated with antidepressant drug response in depression.
Selective serotonin reuptake inhibitors (SSRIs) are not associated with an increased risk of cardiovascular disease, a new study has shown.